Positive data from CTI BioPharma

CTI BioPharma Corp. (Nasdaq: CTIC) reported positive data from a Phase 3 registration-directed trial of pacritinib to treat myelofibrosis lifting the stock price 39 cents to $2.33.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.